A Study to Assess The Knowledge and Attitude Regarding HPV Vaccine Among Female Employees Working at Selected Educational Institution, Greater Noida, Uttar Pradesh
Abstract
The cervix is a part of female reproductive system where the cervical cancer develops. Human Papilloma virus (HPV), a sexually transmitted disease is the major cause of cervical cancer (99%) globally. Most cases of cervical cancer can be prevented with primary (HPV vaccine) and secondary (screening for and treating precancerous lesions) prevention strategies. Globally cervical cancer has been ranked fourth as the most causative factor of female mortality. Around 604000 new cases have been reported every year in which India contributes 20% in it. In developed countries, by early screening 50-60% of cervical cancer has been reduced. The purpose of the study is to assess the knowledge and attitude regarding HPV vaccine among female employees working at selected educational institution. A cross sectional survey design was adapted for the research study, self-structured questionnaire was prepared to gather data the knowledge and attitude towards HPV vaccination and was distributed to 60 female employees working in Sharda University. Data analysis was done using the Likert scale. The result shows that majority (65%) had knowledge about causes of cervical cancer, half of the participants (50%) knew about the detection of cervical cancer (45%) agrees that young girls should be vaccinated, majority (50%) of the participant agrees that cervical cancer is very common, half of the participants agrees (45%) HPV is life threatening, and majority (30%) that they are susceptible to receive vaccination. The result indicates that participants had significant knowledge about the issues but there are few areas that needs to be educated.
References
2. Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, HaieMeder C, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Int J Gynecol Cancer. 2018; 28:641–55. [PubMed] [Google Scholar]
3. Milner DA (2015). Diagnostic Pathology: Infectious Diseases. Elsevier Health Sciences. p. 40. ISBN 978-0-323-40037-4. Archived from the original on 11 September 2017
4. Meyers J, Ryndock E, Conway MJ, Meyers C, Robison R (June 2014). "Susceptibility of high-risk human papillomavirus type 16 to clinical disinfectants". J Antimicrob Chemother. 69 (6): 1546–50. doi:10.1093/jac/dku006. PMC 4019329. PMID 24500190
5. Mitchell M.F., Tortolero-Luna G., Wright T., Sarkar A., Richards-Kortum R., Hong W.K., Schottenfeld D. Cervical human papillomavirus infection and intraepithelial neoplasia: A review. J. natl Cancer Inst. Monogr. 1996;21:17–25.
6. Markowitz LE, Drolet M, Lewis RM, Lemieux-Mellouki P, Pérez N, Jit M, Brotherton JM, Ogilvie G, Kreimer AR, Brisson M. Human papillomavirus vaccine effectiveness by number of doses: updated systematic review of data from national immunization programs. Vaccine. 2022 Sep 2;40(37):5413-32.
7. Zhao FH, Wu T, Hu YM, Wei LH, Li MQ, Huang WJ, Chen W, Huang SJ, Pan QJ, Zhang X, Hong Y. Efficacy, safety, and immunogenicity of an Escherichia coli-produced human papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. The Lancet Infectious Diseases. 2022 Dec 1;22(12):1756-68.
8. Kjaer SK, Van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. Bmj. 2002 Sep 14;325(7364):572.
9. Sankaranarayanan R, Joshi S, Muwonge R, Esmy PO, Basu P, Prabhu P, Bhatla N, Nene BM, Shaw J, Poli UR, Verma Y. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine. 2018 Aug 6;36(32):4783-91.
10. Burger EA, Campos NG, Sy S, Regan C, Kim JJ. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country. Vaccine. 2018 Aug 6;36(32):4823-9
11. Orumaa M, Kjaer SK, Dehlendorff C, Munk C, Olsen AO, Hansen BT, Campbell S, Nygård M. The impact of HPV multi-cohort vaccination: real-world evidence of faster control of HPV-related morbidity. Vaccine. 2020 Feb 5;38(6):1345-51.
12. Yang A, Farmer E, Wu TC, Hung CF. Perspectives for therapeutic HPV vaccine development. Journal of biomedical science. 2016 Dec;23:1-9.
13. Ortiz RR, Smith A, Coyne-Beasley T. A systematic literature review to examine the potential for social media to impact HPV vaccine uptake and awareness, knowledge, and attitudes about HPV and HPV vaccination. Human vaccines &immunotherapeutics. 2019 Aug 3;15(7-8):1465-75.
14. Koc, Z., & Yildirim, F. Awareness of human papillomavirus (HPV) and its relationship with cervical cancer among women in Turkey. Journal of Cancer Education, 2002 37(1), 78-84. https://doi.org/10.1007/s13187-020-01860-x
15. Patel, H., Pandey, S., Bajpai, D., Jain, S., Baro, N., & Basu, P. Awareness of HPV and its vaccine among women from a rural population in India. Journal of Obstetrics and Gynaecology of India, 2020. 70(3), 153-159. https://doi.org/10.1007/s13224-019-01268-4
16. Gupta, A., Kumar, N., & Meena, J. K.. Knowledge, attitude, and practices regarding cervical cancer and screening among women in India: A cross-sectional study. Journal of Family Medicine and Primary Care, 2020. 7(4), 953-958. https://doi.org/10.4103/jfmpc.jfmpc_172_18
17. Singh, M., Devi, R., & Aggarwal, A. Cervical cancer awareness and screening among women in urban slums of India: A cross-sectional study. Indian Journal of Cancer, 2019. 56(1), 47-53. https://doi.org/10.4103/ijc.IJC_458_17
18. Dempsey, A. F., Pyrzanowski, J., & Lockhart, S. HPV vaccine series completion: A systematic review of the literature. Preventive Medicine. 2021 145, 106-401. https://doi.org/10.1016/j.ypmed.2020.106401
